STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms.

Trial Profile

STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2015

At a glance

  • Drugs Tenecteplase (Primary) ; Aspirin; Clopidogrel; Enoxaparin sodium; Enoxaparin sodium
  • Indications Cardiovascular disorders; Myocardial infarction
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms STREAM
  • Most Recent Events

    • 11 Mar 2013 Data presented at the American College of Cardiology 62nd Annual Scientific Sessions and Expo, according to a Boehringer Ingelheim media release.
    • 10 Mar 2013 Primary endpoint `composite of all-cause mortality, cardiogenic shock, congestive heart failure and recurrent myocardial infarction' has been met.
    • 10 Mar 2013 Rationale, trial design and results presented at a late-breaking clinical trial session at the 62nd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top